Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial-Reference-Cited by-同舟云学术

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Published:2022-11 Issue:11 Volume:33 Page:1168-1178
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Griesinger F.,Curigliano G.,Thomas M.,Subbiah V.,Baik C.S.,Tan D.S.W.,Lee D.H.,Misch D.,Garralda E.,Kim D.-W.,van der Wekken A.J.,Gainor J.F.,Paz-Ares L.,Liu S.V.,Kalemkerian G.P.,Houvras Y.,Bowles D.W.,Mansfield A.S.,Lin J.J.,Smoljanovic V.,Rahman A.,Kong S.,Zalutskaya A.,Louie-Gao M.,Boral A.L.,Mazières J.^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. KIF5B-RET fusions in lung adenocarcinoma;Kohno;Nat Med,2012

2. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies;Lipson;Nat Med,2012

3. RET, ROS1 and ALK fusions in lung cancer;Takeuchi;Nat Med,2012

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

5. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden;Hellmann;N Engl J Med,2018

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Development and validation of a novel high-performance liquid chromatography (HPLC) method for the detection of related substances of pralsetinib, a new anti-lung cancer drug;Frontiers in Chemistry;2024-08-21

3. Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database;Expert Opinion on Drug Safety;2024-08-19

4. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

5. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms;Die Onkologie;2024-08-15